Research programme: ruthenium-based chemotherapy - Oncosense

Drug Profile

Research programme: ruthenium-based chemotherapy - Oncosense

Alternative Names: MMI 4403; ONCO 4402; ONCO 4403; ONCO 4417; Ruthenium 4403; Ruthenium 4417

Latest Information Update: 04 May 2010

Price : $50

At a glance

  • Originator University of Edinburgh
  • Developer Oncosense
  • Class Organometallic compounds
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 04 Sep 2009 Discontinued - Preclinical for Cancer in United Kingdom (IV)
  • 29 Mar 2007 Preclinical development is ongoing
  • 06 Oct 2003 Preclinical trials in Cancer in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top